Deals this week: Applied BioMath, Mironid, ApoGen Biotechnologies


Applied BioMath and Tusk Therapeutics NV have entered a co-development agreement to quantify and analyse the drug properties and select pre-clinical drug candidates within immuno-oncology.

Pursuant to the agreement, the two partners will work on developing quantitative system pharmacology (QSP) model for a Tusk Therapeutics’ target and antibody candidates using Applied BioMath’s mechanistic modelling platform.

The agreement allows the two partners to develop pre-clinical drug candidate selection.

Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

As part of the agreement, the two partners will jointly advance the clinical development of Mironid’s LoAc molecules.

The agreement enables the partners to produce new therapies for ADPKD.

"Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD)."

ApoGen Biotechnologies has raised $7m in a series A financing round, which was led by Accelerator Corporation and co-led by AbbVie Biotech Ventures, Alexandria Ventures Investments, ARCH venture Partners, Eli Lilly and Company and Johnson & Johnson Innovation.

The company plans to invest the funds to develop novel drugs to target resistance to cancer therapy.

Achaogen plans for an underwritten public offering of 6.5 million shares of its common stock.

The company expects to raise $87.75m through the offering, which is expected to be completed by 19 December.

Latham & Watkins is acting as the legal advisor for the offering.

The company intends to invest the funds to advance the development, marketing and commercialisation of Plazomicin and fund a variety of capital preservation investments.

Enumeral Biomedical Holdings has raised $3.4m through the private placement of 6.8 million shares of warrants.

The company plans to use the funds for its ongoing operations and for general corporate purposes.